Bioluminescence Ventures

Bioluminescence Ventures, founded in 2022 and based in San Francisco, is a biotechnology venture capital firm dedicated to advancing the future of medicine. The firm invests in innovative companies within the healthcare sector, focusing on translating transformative scientific advancements into next-generation therapies. Bioluminescence Ventures emphasizes four primary areas for investment: Breakthrough Biology, Drug Discovery Platforms, Genetic Medicines Platforms, and Computational Biology Platforms. By concentrating on these sectors, the firm aims to harness the accelerating pace of biomedical innovation to create significant impacts for patients while achieving strong financial returns.

Kouki Harasaki

Managing Partner

4 past transactions

GEMMABio

Seed Round in 2024
GEMMABio is a therapeutics company dedicated to developing gene therapies for individuals with rare diseases. Its mission is to accelerate research and enhance global access to these life-changing treatments, aiming to bring gene therapy discoveries from the lab to patients worldwide more swiftly and affordably.

Cerevance

Series B in 2024
Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Ensoma

Series B in 2023
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Nido Biosciences

Series B in 2023
Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company utilizes a functional genomics discovery platform based on human cell lines to identify novel therapeutic targets, addressing the underlying biology of neurodegenerative diseases. By leveraging advancements in neuroscience and human genetics, Nido aims to create precise medications that restore healthy cell function and improve treatment options for conditions that significantly impact patient quality of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.